Understanding The Success Of CAR T-Cell Therapy In Multiple Myeloma The treatment of multiple myeloma, a bone marrow malignancy, has been transformed by CAR T-cell therapy, especially for patients who have not responded to traditional medicines. This immunotherapy targets the B-cell maturation antigen (BCMA) present on myeloma cells by altering the patient's T-cells to express chimeric antigen receptors (CARs). After being reinfused into the patient, these modified T-cells identify and target the myeloma cells, resulting in a substantial reduction of the tumor. Ongoing research aims to enhance the therapy’s safety and effectiveness, including reducing side effects like cytokine release syndrome and improving the long-term persistence of CAR T-cells. While CAR T-cell therapy is expensive and may not be accessible to all, its success in treating refractory multiple myeloma represents a major advancement in cancer care, offering new hope for many patients. FOR MORE INFORMATION VISIT OUR OFFICIAL SITE:- https://www.edhacare.com/treatments/cancer/car-t-cell-therapy